Needham analyst Serge Belanger lowered the firm’s price target on Pacira to $52 from $60 but keeps a Buy rating on the shares. The company encountered some headwinds in Q2, with the main culprit that continues to be elective surgery volumes, the analyst tells investors in a research note. The firm adds however that July volumes point to improving trends that should continue through the end of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PCRX:
- Pacira price target lowered to $55 from $60 at Truist
- Pacira price target lowered to $63 from $68 at H.C. Wainwright
- Pacira upgraded to Outperform from Market Perform at TD Cowen
- Pacira BioSciences Reports Second Quarter 2023 Financial Results
- Pacira lowers FY23 EXPAREL net product sales view $550M-$560M from $570M-$580M